Most of the M&A talk surrounding REGN centers on REGN being bought out by SNY or other large pharma, but I think REGN may soon become a buyer itself of smaller companies. It will soon have a $20 billion market cap, easily capable of swallowing small promising companies with a phase 3 or even approved drug for $2-3 billion a clip in all-stock transactions. On the cholesterol front, it looks like REGN727 is more effective than Amgen's, but less than Pfizer's. However, REGN will be first to market and should capture a significant chunk of that market.
Agree, and with Dr. Vagelos as Chairmen, I'm sure he has a Rolodex full of the best candidates. Lots of interesting biotechs out there that need cash at present, REGN has plenty, and the cash hord is gonna GROW. I forget what our NOL is, but it's BIG, so no taxs for REGN for a while. I hope they hold on to their stock, and just use cash, THEIR stock is SO much more valuable than cash. GLTA!